GlassScriptPhysician profile
Michelle L Dalton
NPI 1225736499
$3,666.79
in general payments reported to CMS, 2019-2025
24 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $592 · 2024: $1,521 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $478.99 | 2023-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $377.05 | 2024-2025 | |
| Amgen INC. | $362.28 | 2023-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $220.02 | 2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $194.62 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.68 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $192.56 | 2024-2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $175.15 | 2024 | Nexletol |
| Pfizer INC. | $171.90 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $163.60 | 2023-2025 | Spravato, Xarelto |
| Chiesi USA, INC. | $138.66 | 2023-2025 | Cleviprex, Kengreal |
| Nestle Healthcare Nutrition INC. | $122.85 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $121.25 | 2024-2025 | Camzyos, Eliquis |
| Idorsia Pharmaceuticals US INC | $118.85 | 2025 | Tryvio |
| Gilead Sciences, INC. | $117.67 | 2025 | Epclusa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $111.57 | 2024 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $108.13 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $100.92 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $78.46 | 2023-2025 | Verquvo |
| Inspire Medical Systems, INC. | $46.15 | 2023-2024 | Inspire |
| Cvrx, INC. | $27.45 | 2024 | Barostim Neo System |
| Atricure, INC. | $16.65 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Kowa Pharmaceuticals America, INC. | $14.46 | 2024 | Livalo |
| Glaxosmithkline, LLC. | $13.87 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.